# Uncommon Therapeutic Approaches for Patients with Recurrent Central Serous Chorioretinopathy: case report and literature review

## TL;DR

This case report explores the use of anti-VEGF injections for treating a patient with recurring central serous chorioretinopathy, showing positive visual outcomes.

## Contribution

The paper presents a successful case of anti-VEGF treatment for recurrent CSCR, offering insights into its effectiveness.

## Key findings

- Anti-VEGF injections led to good results in a patient with recurrent CSCR.
- The patient's OCT results remained normal six months post-treatment.
- Reduced fluid accumulation and improved vision were observed.

## Abstract

The objective of anti-VEGF (Vascular Endothelial Growth Factor) injections in the treatment of central serous chorioretinopathy (CSCR) is to help reduce fluid accumulation beneath the retina, promote resolution of retinal edema, and potentially prevent complications like permanent vision loss.

The goal is to stabilize or improve vision by improving visual outcomes by reducing fluid and promoting retina reattachment.

A 43-year-old Caucasian male presented with painless, decreased vision in the left eye. The diagnosis of central serous chorioretinopathy was made. After the anti-VEGF injections, the results were good, beyond expectations, and the OCT aspect was maintained at 6 months within normal limits of the foveal affected area without recording extra vision loss.

In CSCR, the retinal pigment epithelium (RPE) becomes compromised, causing fluid from the choroid to leak under the retina, leading to retinal or serous detachment of the macula. While the exact cause of CSCR is not fully understood, it is believed that the increased permeability of the choroidal vessels, often due to elevated VEGF levels, contributes to fluid leakage. The specific goals of using anti-VEGF injections in CSCR include reducing choroidal vascular leakage, promoting fluid reabsorption, and preventing recurrence or progression.

Anti-VEGF agents like aflibercept and ranibizumab are commonly used in treating CSCR, though their effectiveness can vary, and treatment regimens depend on individual patient response. Typically, anti-VEGF injections are administered via intravitreal injection into the eye, with repeat injections, if necessary, based on monitoring the patient’s condition.